CPUY192018, a nuclear factor erythrocyte-2-related factor 2 (Nrf2) activator, can inhibit glycolysis, enhance antioxidant stress, and produce satisfactory therapeutic effects on macrophages of COPD patients and cigarette smoke extract-induced COPD mice, which is expected to be a potential treatment for COPD (Wang L. et al., 2021). The gene discussed is NFE2L2; the disease is chronic obstructive pulmonary disease.